Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
Open Access
- 11 February 2014
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 37 (3) , 666-670
Abstract
OBJECTIVE: Exenatide treatment improves glycemia in adults with type 2 diabetes and has been shown to reduce postprandial hyperglycemia in adolescents with type 1 diabetes. We studied the effects of exenatide on glucose homeostasis in adults with long-standing type 1 diabetes. RESEARCH DESIGN AND METHODS: Fourteen patients with type 1 diabetes participated in a crossover study of 6 months' duration on exenatide (10 μg four times a day) and 6 months off exenatide. We assessed changes in fasting and postprandial blood glucose and changes in insulin sensitivity before and after each study period. RESULTS: High-dose exenatide therapy reduced postprandial blood glucose but was associated with higher fasting glucose concentrations without net changes in hemoglobin A1c. Exenatide increased insulin sensitivity beyond the effects expected as a result of weight reduction. CONCLUSIONS: Exenatide is a promising adjunctive agent to insulin therapy because of its beneficial effects on postprandial blood glucose and insulin sensitivity in patients with type 1 diabetes.Keywords
This publication has 14 references indexed in Scilit:
- Uncoupling Intensive Insulin Therapy from Weight Gain and Hypoglycemia in Type 1 DiabetesDiabetes Technology & Therapeutics, 2011
- The Welcome Resurgence of the α-Cell: A Pro Glucagon CommentaryDiabetes, 2010
- The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 DiabetesDiabetes Care, 2010
- Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 DiabetesDiabetes Care, 2009
- Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usageAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma RemainsEndocrine Reviews, 2007
- Postprandial Hyperglycemia and Diabetes ComplicationsDiabetes, 2005
- Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2004
- Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2003
- Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteersAmerican Journal of Physiology-Endocrinology and Metabolism, 2001